おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Promentis Pharmaceuticals
company
About
Promentis Pharmaceuticals focuses on developing antipsychotic drugs to treat schizophrenia.
- 11 - 50
Details
- Last Funding Type
- Grant
- Last Funding Money Raised
- $1.80M
- Industries
- Biotechnology,Medical,Pharmaceutical
- Founded date
- Jan 1, 2006
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Promentis Pharmaceuticals discovers, develops, and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. Promentis Pharmaceuticals was founded in 2006 and is based in Milwaukee, Wisconsin.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$1.80M
Promentis Pharmaceuticals has raised a total of
$1.80M
in funding over 2 rounds. Their latest funding was raised on
Sep 25, 2012 from a Grant round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Sep 25, 2012 | Grant | $1.80M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Promentis Pharmaceuticals is funded by 1 investors.
National Institutes of Health
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
National Institutes of Health
|
— | Grant |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
